NeoGenomics Q1 revenue up 8% to $168M; adjusted EBITDA turns positive at $7M

NEOGENOMICS INC

Consolidated revenue $168M (+8% YoY); net loss improved 4% to $26M.
Adjusted EBITDA $7M vs $3M prior year, up 102%.
Revenue per clinical test $459 (+3%).
Revised FY2025 guidance: revenue $747-759M, adj. EBITDA $55-58M.
Pathline acquisition adds $12-14M expected revenue to 2025 guidance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.